CN105168651A - Preparation method of traditional Chinese medicinal extract for treating coronary heart disease angina - Google Patents
Preparation method of traditional Chinese medicinal extract for treating coronary heart disease angina Download PDFInfo
- Publication number
- CN105168651A CN105168651A CN201510566537.9A CN201510566537A CN105168651A CN 105168651 A CN105168651 A CN 105168651A CN 201510566537 A CN201510566537 A CN 201510566537A CN 105168651 A CN105168651 A CN 105168651A
- Authority
- CN
- China
- Prior art keywords
- extract
- herba triglochinis
- triglochinis
- herba
- heart disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention belongs to the field of traditional Chinese medicinal extracts and relates to a preparation method of a traditional Chinese medicinal extract for treating coronary heart disease angina. The extract is prepared by the following method: firstly, crushing dry triglochin martimum, adding 15 to 22 times of 50 percent to 60 percent ethanol, performing reflux extraction in a water bath of 60DEG C to 65DEG C for 2 to 4 times, 70 to 75 minutes for each time, combining extracting solution, and recovering the ethanol to obtain a total extraction of the triglochin martimum; secondly, performing column chromatography isolation on the obtained total extraction of the triglochin martimum by using DM-301 type macroporous adsorption resin, wherein the diameter-height ratio of a resin column is 1:7 to 8, and the sample injection volume is 7 to 8BV; eluting with water of 4BV to 5BV to remove impurities, eluting with an eluent of 8 to 9BV, in which the ratio of ethyl acetate to acetone is 5:1, wherein the flowing speed is 2 to 3BV/h, collecting the eluent, and concentrating and drying the eluent to obtain the traditional Chinese medicinal extract.
Description
Technical field:
The invention belongs to Chinese medicine extract field, relate to the preparation method of the Chinese medicine extract for the treatment of angina pectoris.
Technical background:
Coronary atherosclerotic heart disease is coronary artery generation atherosclerotic lesion and causes lumen of vessels stenosis or occlusion, causes myocardial ischemia, anoxia or downright bad and heart disease that is that cause, is usually called as " coronary heart disease ".But the scope of coronary heart disease may be more extensive, also comprises inflammation, thromboembolism etc. and cause luminal stenosis or obturation.Coronary heart disease is divided into 5 large classes by World Health Organization (WHO): silent ischemia (latent coronary heart disease), angina pectoris, myocardial infarction, ischemic heart failure (ischemic heart desease) and sudden death 5 kinds of Clinical types.Stable coronary heart disease and acute coronary syndrome is usually divided in clinical.
Census of population (Chinese MONICA) discovery in 35 ~ 64 years old of 1987 ~ 1993 many provinces and cities of China, most high incidence is 108.7/10 ten thousand (Qingdaos), minimum is 3.3/10 ten thousand (Anhui Chuzhou), have more significant regional difference, northern provinces and cities are generally higher than southern provinces and cities.The prevalence city of coronary heart disease is 1.59%, and rural area is 0.48%, adds up to 0.77%, in rising trend.Coronary heart disease comes first of the cause of death in the U.S. and many developed countries.But from the sixties in 20th century, there is the downward trend of coronary heart disease death rate in the U.S..Have benefited from the effort of the reduction coronary risk factor that the 60-80 age U.S. carries out, mainly control the treatment of risk factor and improvement myocardial infarction.Chinese Urban Residents coronary heart disease death in 2009 is rough and careless is 94.96/10 ten thousand, and rural area is 71.27/10 ten thousand, and city is higher than rural area, and male is higher than women.
The risk factor of coronary heart disease comprises changeable risk factor and unmodifiable risk factor.Understand and intervene the control that risk factor contributes to coronary heart disease.Changeable risk factor has: hypertension, dyslipidemia (T-CHOL is too high or low-density lipoprotein cholesterol is too high, triglyceride is too high, HDL-C too low), overweight/obesity, hyperglycemia/diabetes, bad life style comprises smoking, unreasonable meals (higher fatty acid, hypercholesterolemia, high heat etc.), lacks physical exertion, excessive consumption of alcohol, and socio-psychological factors.Unmodifiable risk factor has: sex, age, family history.In addition, relevant with infection, as cytomegalovirus, Chlamydia pneumoniae, helicobacter pylori etc.
The outbreak of coronary heart disease usually with seasonal variations, excited, physical exertion increases, be satiated with food, a large amount of smoking and to drink etc. relevant.
1. symptom
(1) typical chest pain is brought out because of physical exertion, excited etc., prominent sense precordialgia, mostly is ictal angor or squeezing pain, also can be sense of feeling oppressed.Pain, from after breastbone or pareordia, is upwards radiated to left shoulder, arm, even little finger of toe and the third finger, and rest or buccal nitroglycerin can be alleviated.The position that chest pain is diffused also can relate to cervical region, lower jaw, tooth, abdominal part etc.Under chest pain also can appear at rest state or night, caused by coronary spasm, also claim variant angina pectoris.As chest pain character changes, as the Progressive symmetric erythrokeratodermia chest pain recently occurred, the threshold of pain progressively declines so that pause physical exertion or excited even have a rest or sleep soundly Shi Yike outbreak.Pain is aggravated gradually, frequency conversion, duration extension, dispels inducement or buccal nitroglycerin can not be alleviated, and now often suspects unstable angina.
Anginal classification: generally adopt cardiovascular association of CCSC Canada staging in the world.
I level: daily routines, as walking, cat ladder, without angina pectoris attacks.
II level: daily routines are slightly limited because of angina pectoris.
III level: daily routines are obviously limited because of angina pectoris attacks.
IV level: any physical exertion all can cause angina pectoris attacks.
During generation myocardial infarction, chest pain is violent, and the persistent period long (often exceeding half an hour), nitroglycerin can not be alleviated, and can have Nausea and vomiting, perspiration, heating, even cyanosis, blood pressure drops, shock, heart failure.
(2) should be noted that the symptom of a part of patient and be not true to type, only showing as pareordia discomfort, cardiopalmus or weak, or based on gastrointestinal symptom.Some patient may not have pain, as old people and diabetics.
(3) sudden death about has patient's First-episode coronary heart disease of 1/3 to show as sudden death.
(4) other can with General Symptoms, as heating, perspire, terrified, Nausea and vomiting etc.The patient merging heart failure can occur
2. sign
Without special when patient with angina pectoris does not show effect.Can there is the dimnition of cardiac sound in patient, pericardial friction rub.Concurrent perforation of ventricular septum, dysfunction of papillary muscle person, can hear noise in corresponding site.During arrhythmia, the auscultation rhythm of the heart is irregular.
The treatment of coronary heart disease comprises: 1. living habit changes: smoking cessation limit wine, low-fat low-salt diet, and suitable physical training, controls body weight etc.; 2. Drug therapy: antithrombotic (antiplatelet, anticoagulant), alleviates myocardium keto consumption (beta-blocker), allevating angina pectoris (nitrate esters), adjusts fat stabilize plaque (Statins fat regulation medicine); 3. myocardial revascularization treatment: comprise interventional therapy (intravascular balloon expansion plasty and Stent) and surgery coronary artery bypass grafting.Drug therapy is the basis of all treatments.Get involved and also will adhere to long-term standard medication therapy after surgical operation therapy.Concerning same patient, when being in some stages of disease, available drugs controls ideally, and alone medication effect is often not good when another stage, needs medicine and interventional therapy or surgical operation to share.
The treatment of coronary heart disease:
1. Drug therapy
Object is relief of symptoms, reduces anginal outbreak and myocardial infarction; Delay the development of coronary atherosclerosis, and reduce coronary heart disease death.Specification Drug therapy can reduce the mortality rate of patients with coronary heart disease and the generation of ischemic event more effectively, and improves the clinical symptoms of patient.And for the patient of the serious even total blockage of part vascular lesion, on the basis of Drug therapy, Revascula rization treatment can reduce the mortality rate of patient further.
(1) this class of nitrate esters medicine medicine mainly contains: nitroglycerin, sorbide nitrate (sorbitrate), 5-isosorbide mononitrate, pentaerythritol tetranitrate preparation (nitroglycerin ointment or rubber plaster paster) etc.Nitrate esters medicine is the routine administration of patients with stable angina pectoris.Can sublingual administration nitroglycerin or use nitrolingual spray during angina pectoris attacks.For acute myocardial infarction and functions in patients with unstable angina, first intravenously administrable, stable disease, symptom change oral or skin patch into after improving, can drug withdrawal after pain symptom disappears completely.Nitrate esters medicine continues use can there is drug resistance, and effectiveness declines, and can within 8 ~ 12 hours, take medicine, to reduce drug resistance at interval.
(2) antithrombotic reagent comprises antiplatelet and anticoagulant.Antiplatelet drug mainly contains aspirin, clopidogrel (Plavix), tirofiban etc., can anticoagulant, avoids thrombosis and artery-clogging.Aspirin is choice drug, and maintenance dose is every day 75 ~ 100 milligrams, and all patients with coronary heart disease do not have contraindication should long-term taking.The side effect of aspirin stimulates gastrointestinal, and gastrointestinal ulceration patient will be cautious use of.Coronary intervention is postoperative should adhere to oral clopidogrel every day, usual half a year ~ 1 year.
Anticoagulant comprises unfractionated heparin, Low molecular heparin, semi-annular jade pendant reach liver sodium in the last of the ten Heavenly stems, bivalirudin etc.Be generally used for the acute stage of unstable angina pectoris and myocardial infarction, and in interventional therapeutic technique.
(3) fibrinolytic medicine thrombolytic mainly contains streptokinase, urokinase, tissue-type plasminogen activator etc., and the established thrombosis in solubilized coronary occlusion place, opens blood vessel, recovers blood flow, when showing effect for acute myocardial infarction.
(4) namely beta-Blocking agent beta-blocker has health angina pectoris effect, can prevent arrhythmia again.When nothing is obviously avoided, beta-blocker is a line medication of coronary heart disease.Common drug has: metoprolol, atenolol, bisoprolol and have the carvedilol, arotinolol (Almarl) etc. of the effect of α receptor block concurrently, and dosage should to be reduced to heart rate in target zone.Beta-blocker taboo and situation about being cautious use of have asthma, chronic tracheitis and peripheral blood vessel etc.
(5) calcium channel blocker can be used for the angina pectoris that the treatment of stable angina pectoris and coronary spasm cause.Common drug has: verapamil, Nifedipine controlled-release agent, amlodipine, diltiazem etc.Do not advocate to use fugitive calcium channel blocker, as nifedipine ordinary tablet.
(6) renin-angiotensin system inhibitor comprises angiotensin converting enzyme inhibitor (ACEI), hypertensin 2 receptor antagonist (ARB) and aldosterone antagonists.For acute myocardial infarction or the patient that myocardial infarction merging cardiac insufficiency occurs in the recent period, especially this type of medicine should be used.Conventional ACEI class medicine has: enalapril, benazepril, ramipril, fosinopril etc.As there is obvious dry cough side effect, hypertensin 2 receptor antagonist can be used instead.ARB comprises: valsartan, telmisartan, irbesartan, losartan etc.To note preventing blood pressure in medication process on the low side.
(7) Lipid modulating Lipid modulating is applicable to all patients with coronary heart disease.Coronary heart disease gives statins on change living habit basis, and statins mainly reduces low-density lipoprotein cholesterol, and therapeutic goal is for dropping to 80mg/dI.Common drug has: lovastatin, pravastatin, simvastatin, fluvastatin, atorvastatin etc.Nearest research shows, statins can reduce mortality rate and sickness rate.
2. percutaneous coronary intervention (pci) (PCI)
Percutaneous tranluminal coronary angioplasty (PTCA) applies special bag catheter, coronary stenosis place is delivered to through peripheral arterial (femoral artery or radial artery), the tube chamber that full balloon expandable is narrow, improve blood flow, and the stenosis placing rack expanded, prevention of restenosis.Also can in conjunction with Biochemical analyzer art, turnery art.Be applicable to medicine and control bad stable angina pectoris, unstable angina pectoris and myocardial infarction patient.The first-selected emergency intervention treatment of Acute Stage of Myocardial Infarction, the time is extremely important, more early better.
3. coronary artery bypass grafting (being called for short coronary artery bypass, CABG)
Coronary artery bypass grafting, by recovering the perfusion of myocardial blood flow, is alleviated chest pain and ischemia, is improved the quality of life of patient, and can extend the life of patient.Be applicable to the patient of severe coronary pathological changes, the patient of recurring after can not accepting interventional therapy or treatment, and angina pectoris after myocardial infarction, or when there is the complication such as ventricular aneurysm, mitral incompetence, perforation of ventricular septum, while complication, should row bypass operation of coronary artery.The selection of operation should by intracardiac, cardiac surgeon and patient's codetermination.
The invention provides the preparation method of the Chinese medicine extract for the treatment of angina pectoris.Herba Triglochinis of the present invention is the herb of Juncaginaceae Triglochin plant Triglochin Maritimum L. Trig/ochinmaritimumL..
Summary of the invention:
The object of this invention is to provide a kind of Herba Triglochinis extract.
Another object of the present invention is to provide the preparation method of this extract.
This extract that also provides of the present invention treats the application in angina pectoris and rheumatism joint anti-inflammatory drugs in preparation.
The object of the invention is to realize in the following manner:
The preparation method of the Chinese medicine extract for the treatment of angina pectoris, this Herba Triglochinis extract is adopted and is prepared with the following method:
(1) Herba Triglochinis of drying is pulverized, add 15 ~ 22 times amount 50% ~ 60% ethanol, in 60 DEG C ~ 65 DEG C water-bath reflux, extract, 2 times ~ 4 times, each 70min ~ 75min, merge extractive liquid, reclaims ethanol, obtains Herba Triglochinis total extract extractum;
(2) the Herba Triglochinis total extract extractum DM-301 type macroporous adsorbent resin obtained is carried out column chromatography for separation, resin column blade diameter length ratio is 1: 7 ~ 8, loading volume 7BV ~ 8BV, with the remove impurity of 4BV ~ 5BV water elution, with ethyl acetate: acetone=5: eluant 8BV ~ 9BV eluting of 1, flow velocity is 2BV/h ~ 3BV/h, collect eluent, eluent concentrates, dry, to obtain final product.
Described Herba Triglochinis extract is preferably adopted and is prepared with the following method:
(1) Herba Triglochinis of drying is pulverized, add 15 times amount 60% ethanol, in 60 DEG C of water-bath reflux, extract, 4 times, each 70min, merge extractive liquid, reclaims ethanol, obtains Herba Triglochinis total extract extractum;
(2) the Herba Triglochinis total extract extractum DM-301 type macroporous adsorbent resin obtained is carried out column chromatography for separation, resin column blade diameter length ratio is 1: 7, loading volume 8BV, with the remove impurity of 4BV water elution, with ethyl acetate: acetone=5: the eluant 9BV eluting of 1, flow velocity is 2BV/h, collect eluent, eluent concentrates, dry, to obtain final product.
Described Herba Triglochinis extract, is characterized in that, this Herba Triglochinis extract adopts pharmaceutical methods conventional in pharmacy to be prepared into oral formulations.
Described oral formulations is preferably prepared as tablet, pill, hard capsule, granule, oral liquid.
Described Herba Triglochinis extract can be prepared as follows as hard capsule: get Herba Triglochinis extract, be ground into fine powder, add adjuvant, mixing, loads hard capsule, to obtain final product.
Described Herba Triglochinis extract can be prepared as follows as tablet: get Herba Triglochinis extract, be ground into fine powder, add adjuvant, and mixing, makes granule, and dry, tabletted, to obtain final product.
Herba Triglochinis extract of the present invention is used in preparation treatment angina pectoris medicine or health product.
Herba Triglochinis extract of the present invention is also used in preparation treatment rheumatism joint anti-inflammatory drugs or health product.
Concentration of alcohol belonging to the present invention is volumetric concentration.
Herba Triglochinis extract has supplementing QI and nourishing YIN, effect of activating yang of invigorating blood circulation, and can improve Treating Patients of Angina Pectoris clinical symptoms, myocardial ischemia.Zoopery also shows: the rat with Atherosclerosis Model exists the AS early lesions such as the physaliphore of blood vessel lining cells hypertrophy and interior subcutaneous appearance infection, occurs the MMP-9/TMP-1 imbalance state based on MMP-9 rising.Herba Triglochinis extract is the protein expression by reducing MMP-9, regulates MMP-9/TMP-1 imbalance state, improves blood vessel lining cells hypertrophy, alleviate atherosclerotic lesion degree.
Herba Triglochinis extract obviously can improve uncomfortable in chest, cardiopalmus, symptom of breathing hard, and carries out comprehensive treatment for each paathogenic factor.Significant protective effect, arrhythmia, impact on blood pressure and blood vessel can be had to hypoxic-ischemic cardiac muscle.This studies all patients all completed treatments, and the effective percentage for the treatment of group and matched group is respectively 92.9% and 78.6%, and between group, contrast difference has statistical significance (P < 0.05).LVEF, E value of the rear treatment group for the treatment of and A value are apparently higher than matched group, and contrast difference has statistical significance (P < 0.05).Visible, Herba Triglochinis extract can treat angina pectoris.
Detailed description of the invention
Embodiment 1:
(1) Herba Triglochinis of drying is pulverized 20kg, add 20 times amount 50% ethanol, in 65 DEG C of water-bath reflux, extract, 3 times, each 75min, merge extractive liquid, reclaims ethanol, obtains Herba Triglochinis total extract extractum;
(2) the Herba Triglochinis total extract extractum DM-301 type macroporous adsorbent resin obtained is carried out column chromatography for separation, resin column blade diameter length ratio is 1: 8, loading volume 7BY, with the remove impurity of 5BY water elution, with ethyl acetate: acetone=5: the eluant 8BV eluting of 1, flow velocity is 3BV/h, collect eluent, eluent concentrates, dry, obtains Herba Triglochinis extract 11.2g.
Embodiment 2:
(1) Herba Triglochinis of drying is pulverized 20kg, add 15 times amount 60% ethanol, in 60 DEG C of water-bath reflux, extract, 4 times, each 70min, merge extractive liquid, reclaims ethanol, obtains Herba Triglochinis total extract extractum;
(2) the Herba Triglochinis total extract extractum DM-301 type macroporous adsorbent resin obtained is carried out column chromatography for separation, resin column blade diameter length ratio is 1: 7, loading volume 8BV, with the remove impurity of 4BV water elution, with ethyl acetate: acetone=5: the eluant 9BV eluting of 1, flow velocity is 2BV/h, collect eluent, eluent concentrates, dry, obtains Herba Triglochinis extract 11.5g.
Claims (5)
1. treat the preparation method of Chinese medicine extract of angina pectoris, it is characterized in that, adopt and prepare with the following method:
(1) Herba Triglochinis of drying is pulverized, add 15 ~ 22 times amount 50% ~ 60% ethanol, in 60 DEG C ~ 65 DEG C water-bath reflux, extract, 2 times ~ 4 times, each 70min ~ 75min, merge extractive liquid, reclaims ethanol, obtains Herba Triglochinis total extract extractum;
(2) the Herba Triglochinis total extract extractum DM-301 type macroporous adsorbent resin obtained is carried out column chromatography for separation, resin column blade diameter length ratio is 1: 7 ~ 8, loading volume 7BV ~ 8BV, with the remove impurity of 4BV ~ 5BV water elution, with ethyl acetate: acetone=5: eluant 8BV ~ 9BV eluting of 1, flow velocity is 2BV/h ~ 3BV/h, collect eluent, eluent concentrates, dry, to obtain final product.
2. Herba Triglochinis extract as claimed in claim 1, is characterized in that, this Herba Triglochinis extract adopts pharmaceutical methods conventional in pharmacy to be prepared into oral formulations.
3. Herba Triglochinis extract as claimed in claim 1, is characterized in that, this Herba Triglochinis extract adopts pharmaceutical methods conventional in pharmacy to be prepared into tablet, pill, hard capsule, granule, oral liquid.
4. Herba Triglochinis extract as claimed in claim 1, is characterized in that, this Herba Triglochinis extract is adopted and prepared with the following method: get Herba Triglochinis extract, be ground into fine powder, add adjuvant, and mixing loads hard capsule, to obtain final product.
5. Herba Triglochinis extract as claimed in claim 1, is characterized in that, this Herba Triglochinis extract is adopted and prepared with the following method: get Herba Triglochinis extract, be ground into fine powder, add adjuvant, and mixing, makes granule, and dry, tabletted, to obtain final product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510566537.9A CN105168651A (en) | 2015-09-08 | 2015-09-08 | Preparation method of traditional Chinese medicinal extract for treating coronary heart disease angina |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510566537.9A CN105168651A (en) | 2015-09-08 | 2015-09-08 | Preparation method of traditional Chinese medicinal extract for treating coronary heart disease angina |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105168651A true CN105168651A (en) | 2015-12-23 |
Family
ID=54891406
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510566537.9A Pending CN105168651A (en) | 2015-09-08 | 2015-09-08 | Preparation method of traditional Chinese medicinal extract for treating coronary heart disease angina |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105168651A (en) |
-
2015
- 2015-09-08 CN CN201510566537.9A patent/CN105168651A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Jain et al. | Prevention of cardiovascular diseases with anti-inflammatory and anti-oxidant nutraceuticals and herbal products: an overview of pre-clinical and clinical studies | |
| Lorenzo et al. | Sources, chemistry, and biological potential of ellagitannins and ellagic acid derivatives | |
| CN104366636A (en) | Gynura procumbens compound preparation as well as preparation method and application thereof | |
| CN102151291A (en) | Use of antrodia camphorata for treating diseases | |
| CN111919934A (en) | Safflower Suxin tea for reducing high blood pressure, high blood sugar and protecting cardiovascular and preparation method thereof | |
| CN109395028A (en) | A kind of Ge Jingjia ginseng wine formula and preparation method preventing, treating three high diseases | |
| CN107258929A (en) | A kind of rehabilitation type Chinese medicine edible oil and preparation method thereof | |
| CN112089784A (en) | Application of traditional Chinese medicine composition in preparation of medicine for preventing and treating diseases caused by atherosclerosis | |
| CN102726708A (en) | Health-care food for lowering blood pressure | |
| CN105168651A (en) | Preparation method of traditional Chinese medicinal extract for treating coronary heart disease angina | |
| CN104688955A (en) | Chinese herb extracts for treating coronary heart disease angina and preparation method and application thereof | |
| CN101152223B (en) | Use of poplar leaf phenols extract in preparation of medicine for treating cardiovascular disease | |
| CN115475238A (en) | A Chinese medicinal composition for treating cardiovascular and cerebrovascular diseases | |
| CN103505612A (en) | Traditional Chinese medicine composition containing total flavonoids of sea-buckthorn and preparation method of composition | |
| CN102872455B (en) | Medicament for preventing in-stent restenosis after coronary stent implantation and preparation method | |
| CN102309561B (en) | Pharmaceutical composition used for preventing and treating urarthritis and hyperuricemia | |
| CN103495115B (en) | A kind of to the medicative medicated wine of diabetes tool | |
| CN103055122B (en) | The medicine and preparation method thereof of restenosis after prevention percutaneous transluminal coronary stent implantation | |
| CN102579688B (en) | Blood pressure reducing chrysanthemum and dogbane leaf traditional Chinese medicine preparation | |
| CN109908323A (en) | A kind of compound product production method facilitated human bone marrow's stem cell regenerating and activate suspend mode stem cell | |
| CN109771567A (en) | A kind of formula of Chinese herbal medicine supporting vital QI and dispersing blood stasis toxin expelling tumour | |
| CN108355028A (en) | A kind of Chinese medicine and preparation method thereof for treating myocardial infarction | |
| CN102512640A (en) | Medicament for treating hepatitis B | |
| CN102641480A (en) | Traditional Chinese medicine composite used for treating microcirculation disturbance and preparation method thereof | |
| CN111450183A (en) | A Chinese medicinal composition for treating hyperlipidemia and atherosclerosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20151223 |
|
| WD01 | Invention patent application deemed withdrawn after publication |